Editor's Note: The EV-303 and EV-304 studies have expanded the treatment landscape for muscle-invasive bladder cancer (MIBC) by incorporating perioperative enfortumab vedotin plus pembrolizumab into treatment strategies. At the 2026 European Society for Medical Oncology (ESMO) Congress, the phase III VOLGA study reported positive results. In patients with MIBC who were cisplatin-ineligible, neoadjuvant enfortumab vedotin plus perioperative durvalumab, with or without tremelimumab, significantly improved the primary endpoint of event-free survival (EFS) compared with radical cystectomy (RC) alone: median EFS was not reached versus 12.1 months (HR 0.51; 95% CI, 0.38–0.67; P<0.0001).

VOLGA Study at a Glance

Background

The standard of care for patients with muscle-invasive bladder cancer (MIBC) continues to evolve. Investigators evaluated the efficacy of a treatment strategy consisting of neoadjuvant durvalumab with or without tremelimumab plus enfortumab vedotin (D±T+EV), followed by radical cystectomy (RC) and adjuvant durvalumab with or without tremelimumab (D±T).

Methods

VOLGA was a phase III, randomized, open-label clinical trial enrolling patients with MIBC (stage cT2–T4aN0/1M0 or cT1N1M0) who were ineligible for or declined cisplatin-based treatment and were candidates for RC. Patients were randomized in a 1:1:1 ratio to the D+EV group, D+T+EV group, or control group.

Patients in the D+EV and D+T+EV groups received perioperative D±T (neoadjuvant phase: three cycles of D and two cycles of T; adjuvant phase: nine cycles of D and one cycle of T), together with three cycles of neoadjuvant EV, followed by RC after neoadjuvant treatment. Patients in the control group underwent RC, followed by observation or locally approved adjuvant treatment.

The dual primary endpoints were EFS for the two comparisons (D+EV vs. control and D+T+EV vs. control). Overall survival (OS) was a key secondary endpoint. Safety was also evaluated. The results presented here are from the prespecified interim analysis (data cutoff: March 2, 2026).

Results

A total of 233, 233, and 229 patients were randomized to the D+EV, D+T+EV, and control groups, respectively. RC was completed in 85% of patients in the D+EV group, 79% in the D+T+EV group, and 78% in the control group. In addition, 55% of patients in the D+EV group and 42% in the D+T+EV group completed adjuvant treatment.

The median follow-up for EFS was 22.9 months. Compared with the control group, the D+EV regimen demonstrated significant improvements in both EFS (HR 0.51, 95% CI 0.38–0.67, P<0.0001; 24-month EFS rate: 64% vs. 45%) and OS (HR 0.58, 95% CI 0.40–0.83, P=0.0027; 24-month OS rate: 78% vs. 69%).

The D+T+EV regimen also significantly improved EFS compared with the control group (HR 0.61, 95% CI 0.47–0.80, P=0.0004; 24-month EFS rate: 60% vs. 45%), although the difference in OS did not reach statistical significance. Follow-up is ongoing.

According to local pathological assessments, pathological complete response (pCR) was achieved in 45% of patients in the D+EV group (95% CI, 38.6–51.7), compared with 10% in the control group (95% CI, 6.1–14.2).

Grade 3/4 treatment-related adverse events occurred in 30% of patients in the D+EV group and 42% in the D+T+EV group.

An exploratory analysis of circulating tumor DNA (ctDNA) was also conducted. The results showed that 60% of patients who were ctDNA-positive at baseline achieved ctDNA clearance.

Conclusions

Both dual primary EFS endpoints were met. Perioperative durvalumab combined with three cycles of neoadjuvant EV also demonstrated a significant improvement in OS compared with the control group. The safety profile was consistent with the known safety profiles of the individual agents.

Expert Commentary

During the discussion, Professor Michiel van der Heijden of the Netherlands Cancer Institute, Amsterdam, the Netherlands, noted that the VOLGA results were clearly positive and consistent with those of the EV-303 study, which evaluated EV plus pembrolizumab in patients who were ineligible for cisplatin. The EV-304 study, conducted in cisplatin-eligible patients, had already prompted the U.S. Food and Drug Administration (FDA) to expand the indication for this combination to include perioperative treatment of MIBC. In VOLGA, the safety profile of durvalumab plus enfortumab vedotin was consistent with the known safety profiles of the individual agents.

Professor van der Heijden emphasized that the evidence supporting antibody-drug conjugates (ADCs) combined with immune checkpoint inhibitors in bladder cancer is now substantial and consistent. In contrast, the performance of immune checkpoint inhibitors combined with chemotherapy in bladder cancer has been less consistent, as illustrated by several negative results presented at this year’s congress.

For urothelial carcinoma, multiple ADCs with different targets and payloads are currently under development. A study from China demonstrated encouraging results with disitamab vedotin, a HER2-targeted agent. Considered alongside the data for EV, these findings suggest that the vedotin payload carried by disitamab vedotin has particularly strong activity in urothelial carcinoma.

Professor van der Heijden also noted that several clinical trials are currently investigating ADC strategies targeting topoisomerase in urothelial carcinoma.